Overview

Gender

male

David Morgans, Ph.D., brings more than 25 years of experience in drug discovery and development of small molecules to the company.

Previously, Morgans served as a consultant for the biotech and pharmaceutical industry. Prior to becoming a consultant, he served in a variety of executive roles in research and development and general management at Cytokinetics. While at Cytokinetics, Morgans built and led an integrated preclinical R&D organization to provide five novel drug candidates for clinical studies for potential treatment of cancer, heart failure, ALS and other skeletal muscle disorders.

Prior to Cytokinetics, Morgans served as Vice President of Research for Iconix Pharmaceuticals, Inc. and Vice President of Inflammatory Diseases at Roche Bioscience.

Earlier in his career, Morgans held various positions at Syntex Corporation and was an Assistant Professor of Chemistry at University of California, Santa Cruz.

Morgans holds a B.S. in chemistry from Saint Joseph’s University in Philadelphia and a Ph.D. in chemistry from Columbia University.